Kids & teens (for parents) · Illinois
Studies for children and teens in Illinois
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
75 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Chicago, IL + 12 other US sites
- Eligibility basics
- Ages 13–17
- RecruitingPhase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Hoffmann-La Roche
- Location
- Chicago, IL + 9 other US sites
- Eligibility basics
- Ages 4 mo–2
- RecruitingPhase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
GlaxoSmithKline
- Location
- Normal, IL + 18 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
AstraZeneca
- Location
- Chicago, IL + 18 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited
- Location
- Chicago, IL + 16 other US sites
- Eligibility basics
- Ages 3–12
- RecruitingPhase 2
Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
Vifor Pharma, Inc.
- Location
- Peoria, IL + 9 other US sites
- Eligibility basics
- Ages 0 mo–11
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Naperville, IL + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Chicago, IL + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Elgin, IL + 27 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Chicago, IL + 26 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Evanston, IL + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Chicago, IL + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Chicago, IL + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Optinose US Inc.
- Location
- Springfield, IL + 18 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Neurocrine Switzerland GmbH
- Location
- Chicago, IL + 10 other US sites
- Eligibility basics
- Ages 4 mo–3
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Chicago, IL + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Chicago, IL + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Bristol-Myers Squibb
- Location
- Chicago, IL + 4 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
Takeda
- Location
- Peoria, IL + 9 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Takeda
- Location
- Rolling Meadows, IL + 10 other US sites
- Eligibility basics
- Ages 4–17
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Skokie, IL + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 1/Phase 2
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
Jaguar Gene Therapy, LLC
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Ages 2–9
- RecruitingPhase 1/Phase 2
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
Astellas Gene Therapies
- Location
- Chicago, IL + 3 other US sites
- Eligibility basics
- Up to age 3 · Men only
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Chicago, IL + 14 other US sites
- Eligibility basics
- Ages 10–17